Proteomic mechanistic profile of patients with diabetes at risk of developing heart failure: insights from the HOMAGE trial

Proteomic mechanistic profile of patients with diabetes at risk of developing heart failure: insights from the HOMAGE trial

Abstract Background Patients with diabetes mellitus (DM) are at increased risk of developing heart failure (HF). The “Heart OMics in AGEing” (HOMAGE) trial suggested that spironolactone had beneficial effect on fibrosis and cardiac remodelling in an at risk population, potentially slowing the progre...

Full description

Bibliographic Details
Main Authors: Job A. J. Verdonschot, João Pedro Ferreira, Pierpaolo Pellicori, Hans-Peter Brunner-La Rocca, Andrew L. Clark, Franco Cosmi, Joe Cuthbert, Nicolas Girerd, Beatrice Mariottoni, Johannes Petutschnigg, Patrick Rossignol, John G. F. Cleland, Faiez Zannad, Stephane R. B. Heymans, HOMAGE “Heart Omics in AGEing” consortium
Format: Article
Language:English
Published: BMC 2021-08-01
Series:Cardiovascular Diabetology
Subjects:
Diabetes
Biomarker
Heart failure
Spironolactone
Fibrosis
Online Access:https://doi.org/10.1186/s12933-021-01357-9

Internet

https://doi.org/10.1186/s12933-021-01357-9

Similar Items